finafloxacin

Clinical Therapeutics
Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections
F. Wagenlehner, M. Nowicki, C. Bentley, M. Lückermann, S. Wohlert, C. Fischer, A. Vente, K. Naber, A. Dalhoff
Clinical Therapeutics
Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized Isolates
Andreas Vente, Christine Bentley, Mark Lückermann, Paul Tambyah, Axel Dalhoff
Pharmacology
Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients with Complicated Urinary Tract Infections
Max Taubert, Mark Lückermann, Andreas Vente, Axel Dalhoff, Uwe Fuhr
Pharmacology
Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers
Max Taubert, Joseph Chiesa, Mark Lückermann, Carsten Fischer, Axel Dalhoff, Uwe Fuhr
Open Access

Experimental Therapeutics
Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei
Kay B. Barnes, Karleigh A. Hamblin, Mark I. Richards, Thomas R. Laws, Andreas Vente, Helen S. Atkins, Sarah V. Harding
Open Access

Experimental Therapeutics
Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections
A. Dalhoff, S. Schubert, A. Vente